NeuroSense Therapeutics Ltd. Deferred Tax Assets, Valuation Allowance
NeuroSense Therapeutics Ltd. (NRSN) had Deferred Tax Assets, Valuation Allowance of $10.14 million as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $10.14M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $7.13M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $4.83M; Deferred Tax Assets, Valuation Allowance as first filed $4.76M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $3.02M; Deferred Tax Assets, Valuation Allowance as first filed $2.09M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $10.14M 20-F · filed 2026-03-31 | |
| 2024-12-31 | $7.13M 20-F · filed 2026-03-31 | |
| 2023-12-31 | $4.83M 20-F · filed 2026-03-31 | $4.76M 6-K · filed 2024-06-17 |
| 2022-12-31 | $3.02M 20-F · filed 2026-03-31 | $2.09M 6-K · filed 2024-06-17 |
| 2021-12-31 | $1.61M 20-F · filed 2025-04-07 | $953.00K 6-K · filed 2024-06-17 |